SGX PHARMACEUTICALS, INC. (SGXP) is a publicly traded company in the Unknown sector. Across all available filings, 16 corporate insiders have executed 150 transactions totaling $17.3M, demonstrating a bullish sentiment with $16.9M in net insider flow. The most recent transaction on Aug 20, 2008 involved a transaction of 100,000 shares valued at $300.0K.
No significant insider buying has been recorded for SGXP in the recent period.
No significant insider selling has been recorded for SGXP in the recent period.
Based on recent SEC filings, insider sentiment for SGXP is bullish with an Insider Alignment Score of 99/100 and a net flow of $16.9M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at SGX PHARMACEUTICALS, INC. (SGXP) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 16 insiders are actively trading SGXP stock, having executed 150 transactions in the past 90 days. The most active insider is Value Fund II Lp Biotechnology (Executive), who has made 3 transactions totaling $16.5M.
Get notified when executives and directors at SGXP file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Aug 20, 2008 | G. Grey Michael | Executive | Disposition | 100,000 | $3.00 | $300.0K | |
| Aug 20, 2008 | Burley Stephen | Executive | Disposition | 55,731 | $3.00 | $167.2K | |
| Aug 20, 2008 | Todd Myers W. | Executive | Disposition | 25,005 | $3.00 | $75.0K | |
| Aug 20, 2008 | Reich Siegfried | Executive | Disposition | 24,223 | $3.00 | $72.7K | |
| Aug 20, 2008 | S. Henney Christopher | Executive | Disposition | 97,165 | $3.00 | $291.5K | |
| Aug 20, 2008 | Eastham Karin | Executive | Disposition | 12,500 | $3.00 | $37.5K | |
| Aug 20, 2008 | C. Bock Louis | Executive | Disposition | 2,546,747 | $3.00 | $7.6M | Large |
| Aug 20, 2008 | Bavp, L.p. | Executive | Disposition | 2,546,747 | $3.00 | $7.6M | Large |
| Aug 20, 2008 | Fund II Lp Biotechnology Value | Executive | Disposition | 914,700 | $3.00 | $2.7M | Large |
| Aug 20, 2008 | Fund II Lp Biotechnology Value | Executive | Disposition | 3,250,200 | $3.00 | $9.8M | Large |
| Aug 20, 2008 | Fund II Lp Biotechnology Value | Executive | Disposition | 1,342,774 | $3.00 | $4.0M | Large |
| Aug 15, 2008 | Reich Siegfried | Executive | Option Exercise | 1,562 | $N/A | $0 | |
| Aug 15, 2008 | Reich Siegfried | Executive | Sale | 781 | $2.98 | $2.3K | |
| Aug 5, 2008 | Todd Myers W. | Executive | Option Exercise | 1,563 | $N/A | $0 | |
| Aug 5, 2008 | Todd Myers W. | Executive | Sale | 781 | $2.96 | $2.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Disposition(D) | 11 | $32.7M | 65.4% |
Purchase(P) | 20 | $17.1M | 34.2% |
Sale(S) | 62 | $192.7K | 0.4% |
Exercise(M) | 41 | $0 | 0.0% |
Conversion(C) | 16 | $0 | 0.0% |
Insiders at SGX PHARMACEUTICALS, INC. are accumulating shares at an accelerated pace. With 16 insiders making 150 transactions totaling $17.1M in purchases versus $192.7K in sales, the net buying activity of $16.9M signals strong executive confidence. Value Fund II Lp Biotechnology (Executive) leads the buying activity with $16.5M in transactions across all time.